IDV vehicle
36E79723D0016
NEW AWARD FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC . PERIOD OF PERFORMANCE IS MAY 27, 2023 THROUGH MAY 26, 2024 WITH FOUR ONE YEAR OPTION YEARS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $1.4M |
| Start date | May 27, 2023 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Sep 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 11 of 11 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 10, 2026 | P00010 | $0 | THIS MODIFICATION INCORPORATES SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026), INTO EXISTING NATIONAL CONTRACT 36E79723D0016. |
| Apr 1, 2026 | P00009 | $0 | EXERCISE 3RD OPTION YEAR FOR ATROPINE/DIPHENOXYLATE HCL TABLETS, EFFECTIVE MAY 27, 2026 THROUGH MAY 26, 2027 WITH NO PRICE CHANGES |
| Dec 31, 2025 | P00008 | $0 | INCORPORATE SPECGX 2026 SUBCONTRACTING PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE JANUARY 1, 2026 THROUGH DECEMBER 31, 2026. |
| Apr 8, 2025 | P00007 | $0 | EXERCISE OPTION YEAR 2 FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE MAY 27, 2025 THROUGH MAY 26, 2026. PRICES REMAIN UNCHANGED. |
| Jan 30, 2025 | P00006 | $0 | REVISED 2025 SUBCONTRACTIN PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 1/1/2025 THROUGH 12/31/2025. PRICES REMAIN UNCHANGED. |
| Jan 15, 2025 | P00005 | $0 | 2025 SUBCONTRACTIN PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 1/1/2025 THROUGH 12/31/2025. PRICES REMAIN UNCHANGED. |
| Apr 10, 2024 | P00004 | $0 | EXERCISE OPTION YEAR ONE FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 5/27/2024 THROUGH 5/26/2025. PRICES REMAIN UNCHANGED. |
| Feb 13, 2024 | P00003 | $0 | 2024 SUBCONTRACTING PLAN FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 1/1/2024-12/31/2024 |
| Feb 9, 2024 | P00002 | $0 | COST RECOVERY FEE AND SUBMISSION OF QUARTERLY SALES REPORT FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 2/9/2024. |
| Apr 14, 2023 | P00001 | $0 | INCORPORATE DSCSA FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC EFFECTIVE 5/15/2023. |
| Feb 8, 2023 | 0 | $0 | NEW AWARD FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC . PERIOD OF PERFORMANCE IS MAY 27, 2023 THROUGH MAY 26, 2024 WITH FOUR ONE YEAR OPTION YEARS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Adrienne A Albachiara | Contracting Officer | Adrienne.Albachiara@va.gov | Source | Dec 12, 2022 |
| Adrienne A Albachiara | Contracting Officer | Adrienne.Albachiara@va.gov | Source | Nov 28, 2022 |
| Adrienne A. Albachiara | Contract Specialist | adrienne.albachiara@va.gov 708-512-7383 | Source | Nov 18, 2022 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.